AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$ZOMDF

Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity

Zomedica Corp. (ZOMDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity Zomedica surpasses $9 million in quarterly revenue for the second quarter in a row while extending its record of consecutive ye

Original reporting
SEC EDGAR 8-K
Published Nov 4, 2026, 9:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ZOMDF
Bullish
high confidence
Mentioned
$ZOMDF
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ZOMDFBullishMed
01

Why it matters

The earnings release provides the first fresh set of financial metrics for the company in 2026, highlighting strong revenue growth and improved cost discipline.

02

Market read

First‑report earnings for a micro‑cap animal‑health firm; could trigger short‑term price movement in OTC markets.

03

What to watch

The impact of the Boehringer Ingelheim partnership and international expansion may take longer to materialize, and the small cash runway could constrain growth.

Relevance 7/10Novelty 6/10Timing: today

Background

Zomedica (OTCQB: ZOMDF) is an animal‑health company focused on point‑of‑care diagnostics and therapeutic devices for equine and companion animals.

Company-level read

Ticker impact

$ZOMDFBullishHigh confidence
Context

Zomedica reported record Q3 revenue of $9.9M, 22% YoY growth and a 48% reduction in net loss, plus $41M liquidity.

Expected impact

potential modest upside as investors price in stronger top‑line growth and better cash discipline

Evidence & confidence

The company posted its first quarterly profit‑related metrics in years with significant revenue acceleration and lower operating expenses, which are new and material for a micro‑cap.

Market effects

Sector

Animal health diagnostics may see renewed investor interest as Zomedica's growth validates the market.

Regional

U.S. OTC market may see slight buying pressure in similar small‑cap biotech/animal‑health stocks.

Global

Limited to niche sector; no broad macro impact.

Counterpoint

What could challenge this read

Despite revenue growth, the company remains loss‑making and cash‑burn dependent on future product adoption, which could limit upside.

Key entities

  • Executive
    Larry Heaton

    Chief Executive Officer of Zomedica, quoted on the earnings results.

  • Partner
    Boehringer Ingelheim Animal Health

    Collaborator mentioned as supporting diagnostic revenue growth.

Read at source← All news

Related articles

$ZOMDFMedAI 9/10

Zomedica Corp.: Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity

Zomedica Corp. (OTCQB:ZOMDF) reported record Q2 2026 revenue of $9.5 million, up 37% year over year, with gross margin of 64%. Operating expenses fell 20% to $10.1 million and cash burn improved 38% to $3.4 million. The company said liquidity totaled $44.1 million and cited growth in Diagnostics, Therapeutic Devices, and Development Services.

finanznachrichten.de
$ZOMDFMed

Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity

Zomedica Corp. (ZOMDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity Zomedica surpasses $9 million in second quarter revenue for the first time while extending its record of consecutive year-ov

SEC EDGAR 8-K
$AMCHighAI 8/10

Why Did AAPL, MSFT, AMC Stocks Surge To 52-Week Highs?

AAPL, MSFT, and AMC stocks reached 52-week highs. Pershing Square cited MSFT's AI growth potential via Azure, Copilot, and GitHub. AMC reported record Q3 revenue of $1.71B and adjusted EBITDA of $347.5M, with CEO Adam Aron attributing success to loyalty programs and cost management. Retail sentiment improved for both MSFT and AMC.

finance.yahoo.com
$CNKHigh

Morgan Stanley upgrades Cinemark stock rating on box office outlook

Morgan Stanley upgraded Cinemark (CNK) to Overweight with a $50 price target, citing optimism about 2027 box office growth and the company's strong market position. Cinemark's stock has risen 75.3% year-to-date, trading near its 52-week high. The company reported record Q3 earnings of $1.04 per share on $1.06 billion revenue, exceeding expectations. Other analysts have also raised their price targets following the strong performance.

investing.com